|
FY2024
12 months to Sep 30, 2024
|
FY2023
12 months to Sep 30, 2023
|
|
|---|---|---|
| Revenue | ||
| Products | ||
| Services | ||
| Others | ||
| Total revenue | ||
| Cost of sales | ||
| Gross profit | ||
| Operating expenses | ||
| Marketing and product management | ||
| Selling | ||
| General and administrative | ||
| Stock based compensation | ||
| Research and development costs (net of R&D tax credits of $176,857 in 2024, $225,609 in 2023 and $70,191 in 2022) | ||
| Listing expense | ||
| Restructuring costs | ||
| Impairment loss related to intangible assets | ||
| Impairment loss related to goodwill and intangible assets | ||
| Total, operating expenses | ||
| Loss from operations | ||
| Other (income) costs | ||
| Grant revenue | ||
| Grant revenue | ||
| Finance costs (income), net | ||
| Loss before income taxes from continuing operations | ||
| Income taxes | ||
| Net loss and comprehensive loss from continuing operations | ||
| Discontinued operations | ||
| Net income (loss) and comprehensive income (loss) from discontinued operations | ||
| Net loss and comprehensive loss | ||
| Attributable to: | ||
| Non-controlling interests | ||
| Equity holders of the parent | ||
| Earnings per share | ||
| Net loss per common share, basic (in Dollars per share) | ||
| Net loss per common share, diluted (in Dollars per share) | ||
| Weighted average common shares outstanding, basic (in Shares) | ||
| Weighted average common shares outstanding, diluted (in Shares) | ||
| Earnings per shares for continuing operations | ||
| Net loss from continued operations per common share, basic (in Dollars per share) | ||
| Net loss from continued operations per common share, diluted (in Dollars per share) |
Loading...
